Patterns of recurrence among adults diagnosed with screen-detected lung cancer
Recommended Citation
Carroll NM, Eisenstein J, Wain KF, Freml JM, Greenlee RT, Honda SA, Neslund-Dudas C, Rendle KA, Vachani A, and Ritzwoller DP. Patterns of recurrence among adults diagnosed with screen-detected lung cancer. Cancer Epidemiol 2025; 95:102777.
Document Type
Article
Publication Date
4-1-2025
Publication Title
Cancer Epidemiol
Abstract
BACKGROUND: With the recent shift in lung cancer staging towards early-stage disease coinciding with the introduction of lung cancer screening (LCS), little is known if LCS has affected the rate of recurrence and survival in community settings. Our objective was to evaluate variation in the detection and outcomes of recurrent lung cancer stratified by receipt of LCS.
METHODS: Patients aged 55-80 years old diagnosed with stage I-IIIA non-small cell lung cancer (NSCLC) between 1/1/2014 and 12/31/2020 who completed definitive therapy and were considered disease-free were identified. Rates of recurrence were calculated in discrete 12-month intervals and by cumulative incidence. Survival was evaluated by multivariable adjusted Restricted Mean Survival Time (aRMST). Factors associated with recurrence were evaluated by Poisson models.
RESULTS: Among 916 patients meeting study criteria, 708 (77 %) were non-screen-detected and 208 (23 %) were considered screen-detected. The proportion of recurrence between non-screen-detected (22 %) and screen-detected (17 %) was similar (P = 0.11). Recurrence rates during the first and second years after definitive therapy were 10.1 and 4.1 per 100 person-years for the non-screen-detected and 6.0 and 4.5 per 100 person-years for screen-detected, respectively. Two-year cumulative incidence of recurrence was 16.5 % (95 % CI, 13.9 %-19.4 %) for non-screen-detected patients and 13.8 % (95 % CI, 9.3 %-19.0 %) in the screen-detected group. Recurrence-free survival and survival after recurrence were similar between the two groups. Screening status was not associated with the likelihood of recurrence (RR=0.94, 95 % CI, 0.59-1.50).
CONCLUSION: These findings provide evidence of recurrence being a part of the intrinsic nature of disease progression despite mode of detection. Our findings emphasize the need for all patients to receive surveillance and survivorship care after treatment for early-stage NSCLC regardless of mode of detection. Further study with longer follow-up is warranted.
Medical Subject Headings
Lung Neoplasms; Humans; Male; Female; Middle Aged; Aged; Aged, 80 and over; Recurrence; Neoplasm Recurrence, Local; Neoplasm Staging; Tomography, X-Ray Computed; Early Detection of Cancer
PubMed ID
39970848
Volume
95
First Page
102777
Last Page
102777